Furthermore, several combination targets for CAR-T therapy in MM are under investigation, building on the success of bispecific antibodies, including BCMA/CD3, GPRC5D/CD3 and BCMA/CD19 57. Here, TNFRSF17 is linked to Miyoshi myopathy.